Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 11/20 | 0.36 |
| ▸ | DRD3 | P35462 | 3/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.32 |
| ▸ | DRD1 | P21728 | 2/20 | 0.32 |
| ▸ | DRD4 | P21917 | 2/20 | 0.32 |
| ▸ | DRD5 | P21918 | 2/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4512149 | 0.90 | HSD11B1 (0.35) | HSD11B1FFAR4DRD3DRD2DRD1 | |
| SCHEMBL474701 | 0.82 | HSD11B1 (0.36) | HSD11B1FFAR4DRD3DRD2DRD1 | |
| SCHEMBL474649 | 0.82 | HSD11B1 (0.36) | HSD11B1FFAR4DRD3DRD2DRD1 | |
| SCHEMBL13675470 | 0.82 | FFAR4 (0.36) | HSD11B1FFAR4DRD3OPRM1OPRD1 | |
| SCHEMBL13675471 | 0.79 | SLC6A9 (0.42) | HSD11B1FFAR4 | |
| SCHEMBL208795 | 0.79 | HSD11B1 (0.48) | HSD11B1DRD3DRD2DRD1DRD4 | |
| SCHEMBL474822 | 0.78 | HSD11B1 (0.37) | HSD11B1DRD3DRD2DRD1DRD4 | |
| SCHEMBL474821 | 0.78 | HSD11B1 (0.37) | HSD11B1DRD3DRD2DRD1DRD4 | |
| SCHEMBL474888 | 0.78 | HSD11B1 (0.37) | HSD11B1DRD3DRD2DRD1DRD4 | |
| SCHEMBL13675467 | 0.78 | HSD11B1 (0.39) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885FFAR4 1012/4885DRD3 3583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.